Table 1.
Patient characteristics
| ICBT (n = 280) | HBT (n = 189) | P-value | ||
|---|---|---|---|---|
| Age (median), years | 55 (26-86) | 58 (26-81) | 0.237 | |
| Follow-up period (median), months | 55.3 (2.1-139.9) | 44.6 (3.0-105.3) | <0.001* | |
| FIGO stage (2008) | ||||
| IB2-II | 189 (67.5%) | 75 (39.7%) | <0.001* | |
| III-IVA | 91 (32.5%) | 114 (60.3%) | ||
| Histological subtypes | ||||
| Squamous cell carcinoma | 268 (95.7%) | 170 (89.9%) | 0.005* | |
| Adenocarcinoma | 7 (2.5%) | 17 (9%) | ||
| Adenosquamous carcinoma | 5 (1.8%) | 2 (1.1%) | ||
| Uterine body invasion | ||||
| Yes | 90 (32.1%) | 92 (48.7%) | <0.001* | |
| No | 190 (67.9%) | 96 (50.8%) | ||
| N/A | 0 (0%) | 1 (0.5%) | ||
| Pyometra | 0.140 | |||
| Yes | 77 (27.5%) | 148 (78.3%) | ||
| No | 203 (72.5%) | 41 (21.7%) | ||
| Parametrium invasion | 0.013* | |||
| Yes | 232 (82.9%) | 171 (90.5%) | ||
| No | 48 (17.1%) | 18 (9.5%) | ||
| Hydronephrosis | <0.001* | |||
| Yes | 38 (13.6%) | 58 (30.7%) | ||
| No | 242 (86.4%) | 131 (69.3%) | ||
| Pelvic LN metastasis | ||||
| Yes | 147 (52.5%) | 106 (56.1%) | 0.445 | |
| No | 133 (47.5%) | 83 (43.9%) | ||
| Tumor size at diagnosis (median, cm) | 5.4 (4.0-12.0) | 5.7 (4.1-14.5) | 0.001* | |
| Tumor size before brachytherapy (median, cm) | 3.8 (0.0-6.6) | 4.3 (2.0-10.3) | <0.001* | |
| Reduction ratio (%) | 31 (0-100) | 25 (0-71) | <0.001* | |
| Total treatment time (median, weeks) | 7 (5-11) | 7 (5-14) | 0.600 | |
FIGO: the International Federation of Gynecology and Obstetrics
LN: lymph node
ICBT: intracavitary brachytherapy
HBT: hybrid brachytherapy
*Statistical significance was defined as a P-value of <0.05.